|Bid||42.34 x 900|
|Ask||44.79 x 800|
|Day's Range||42.81 - 44.12|
|52 Week Range||42.29 - 73.89|
|Beta (3Y Monthly)||1.46|
|PE Ratio (TTM)||54.34|
|Earnings Date||Jul 31, 2019 - Aug 5, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||68.67|
Emergent Biosolutions Inc NYSE:EBSView full report here! Summary * Bearish sentiment is low and declining Bearish sentimentShort interest | PositiveShort interest is low for EBS with fewer than 5% of shares on loan. Additionally, this was an improvement in sentiment as investors who seek to profit from falling equity prices reduced their short positions on May 14. Money flowETF/Index ownership | NeutralETF activity is neutral. The net inflows of $2.43 billion over the last one-month into ETFs that hold EBS are not among the highest of the last year and have been slowing. Economic sentimentPMI by IHS Markit | NeutralAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to firstname.lastname@example.org.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.
GAITHERSBURG, Md., May 20, 2019 -- Emergent BioSolutions Inc. (NYSE: EBS) announced today that it has successfully obtained marketing authorization for its oral typhoid vaccine.
GAITHERSBURG, Md., May 20, 2019 -- Emergent BioSolutions Inc. (NYSE: EBS) announced today that a member of the company’s senior management team will participate in the.
Emergent BioSolutions Inc. (EBS) announced today that the Biomedical Advanced Research and Development Authority (BARDA) has informed the company that it will begin procuring AV7909 (anthrax vaccine adsorbed with CPG 7909 adjuvant) for delivery into the Strategic National Stockpile (SNS). Subject to the fulfillment of certain contractual obligations, the company plans to deliver AV7909 in the second half of 2019 under the terms of its development and procurement contract with BARDA valued at up to $1.5 billion signed in September 2016. This milestone and the initiation of the Phase 3 trial of AV7909 in March build upon the application that was submitted in December 2018 to the U.S. Food and Drug Administration (FDA) for the potential emergency use of AV7909 in the event of a public health emergency involving Bacillus anthracis.
GAITHERSBURG, Md., May 09, 2019 -- Emergent BioSolutions Inc. (NYSE: EBS) has announced that it will hold its Annual Meeting of Stockholders on Thursday, May 23, 2019 beginning.
Emergent Biosolutions (EBS) delivered earnings and revenue surprises of -200.00% and -6.88%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
On a per-share basis, the Gaithersburg, Maryland-based company said it had a loss of 51 cents. Losses, adjusted for non-recurring costs, were 13 cents per share. The results did not meet Wall Street expectations. ...
Reaffirms full year 2019 financial forecast and operational goalsProvides Q2 2019 revenue forecast of $200M-$220M GAITHERSBURG, Md., May 02, 2019 -- Emergent BioSolutions Inc..
Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift card! The most recent earnings announcement Emergent BioSolutions Inc.'s (NYSE:EBS) released in December 20...
Looking for stocks with high upside potential? Just follow the big players within the hedge fund industry. Why should you do so? Let’s take a brief look at what statistics have to say about hedge funds’ stock picking abilities to illustrate. The Standard and Poor’s 500 Index returned approximately 13.1% in the 2.5 months of 2019 (including […]
Emergent Biosolutions (EBS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
The Food and Drug Administration has given Israeli drugmaker Teva Pharmaceuticals Inc. final approval to market the first generic naloxone nasal spray to treat opioid overdose, the agency announced Friday. The spray, currently sold under the brand name Narcan by Emergent BioSolutions Inc. subsidiary Adapt Pharma, is a life-saving medication that can stop or reverse the effects of an opioid overdose. Shares of Teva have lost 6.9% so far this year, while the S&P 500 has gained 15.9%. Shares of Emergent BioSolutions have fallen 10.6%. This marks the first time a generic naloxone nasal spray has been approved for use by people without medical training, though generic injectable naloxone products have been available for years. "In the wake of the opioid crisis, a number of efforts are underway to make this emergency overdose reversal treatment more readily available and more accessible. In addition to this approval of the first generic naloxone nasal spray, moving forward we will prioritize our review of generic drug applications for naloxone," said Douglas Throckmorton, deputy center director for regulatory programs in the FDA's Center for Drug Evaluation and Research, in a statement. The U.S. in the midst of a deadly opioid epidemic. Almost 400,000 people died from opioid overdose between 1999 and 2017, according to the Centers for Disease Control and Prevention.
GAITHERSBURG, Md., April 18, 2019 -- Emergent BioSolutions Inc. (NYSE: EBS) will host a conference call on Thursday, May 2, 2019 at 5:00 pm (Eastern Time) to discuss the.
Emergent (EBS) posts interim data from the phase II study on its chikungunya vaccine, CHIKV-VLP. The candidate generates positive immune response against the chikungunya virus.
The interim analysis has shown that with a single dose administered, up to 98% of study participants produced a neutralizing antibody response against the chikungunya virus (CHIKV) by Day 7. Further, the immune response was shown to be persistent through the six-month visit, including in the one-dose regimen.
After Emergent BioSolutions Inc.'s (NYSE:EBS) earnings announcement in December 2018, analysts seem extremely confident, with profits predicted to ramp up by an impressive 72% n...